Type 2 Diabetes Mellitus (T2DM)
Metabolic·MeSH: Diabetes Mellitus, Type 2
Prevalence
10700.0 / 100K
Incidence
600.0 / 100K/yr
7 drugs in development·6 companies·19 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Dulaglutide | ELI LILLY & Co (LLY) |
Phase 2(3)
Phase 1(1)
| Drug | Company |
|---|---|
| AGTX-2004 (DBPR211) | Agentix Corp. (AGTX) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ALN-KHK | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Phase 4(1)
| Drug | Company |
|---|---|
| Semaglutide | UNITED THERAPEUTICS Corp (UTHR) |
Compare drugs
Frequently asked questions
How many drugs are in development for Type 2 Diabetes Mellitus (T2DM)?
BioSniper tracks 7 drugs in development for Type 2 Diabetes Mellitus (T2DM) across 6 companies.
How many clinical trials target Type 2 Diabetes Mellitus (T2DM)?
There are 19 clinical trials targeting Type 2 Diabetes Mellitus (T2DM) tracked by BioSniper.
What is the prevalence of Type 2 Diabetes Mellitus (T2DM)?
The estimated prevalence of Type 2 Diabetes Mellitus (T2DM) is approximately 10700.0 per 100,000 population.
Deep-dive into Type 2 Diabetes Mellitus (T2DM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis